What is the recommended management of dengue fever, including fluid therapy, monitoring, and contraindicated medications?

Management of Dengue Fever

For dengue shock syndrome, initiate aggressive fluid resuscitation with crystalloids at 20 mL/kg boluses, with colloids reserved for severe shock (pulse pressure <10 mmHg) unresponsive to crystalloids, while avoiding NSAIDs and using acetaminophen for fever control. 1

Fluid Therapy Strategy

Initial Resuscitation in Shock

• Administer crystalloid bolus of 20 mL/kg immediately for patients presenting with dengue shock syndrome, followed by careful reassessment 1
• Continue aggressive fluid resuscitation for 24-48 hours, as more than 4 L may be required in the first 24 hours for adults 1
• Switch to colloid solutions only in severe dengue shock syndrome (pulse pressure <10 mmHg) when crystalloids fail to restore adequate tissue perfusion 1
• Moderate dengue shock (pulse pressure 10-20 mmHg) responds equally well to crystalloids or colloids, making crystalloids the preferred first-line choice 1

Monitoring Endpoints

Target adequate tissue perfusion as the primary endpoint, assessed by: 1

• Normal capillary refill time (<2-3 seconds in adults <65 years)
• Warm, dry extremities with well-felt peripheral pulses
• Absence of skin mottling
• Return to baseline mental status
• Urine output >0.5 mL/kg/hour (adults) or >1 mL/kg/hour (children)
• Systolic blood pressure ≥90 mmHg in adults

Critical caveat: Blood pressure alone is unreliable for assessing tissue perfusion adequacy—patients may achieve normal blood pressure without adequate tissue perfusion 1

Vasopressor Support

• Use dopamine or epinephrine (adrenaline) only when tissue hypoperfusion persists despite liberal fluid resuscitation 1
• Administer through central venous catheter when available; if unavailable, use large-bore peripheral IV with frequent monitoring for extravasation 1
• Add hydrocortisone (up to 300 mg/day) or prednisolone (up to 75 mg/day) in adults requiring escalating vasopressor doses 1

Contraindicated Medications

Absolutely avoid NSAIDs (except potentially ibuprofen—see below) and aspirin due to bleeding risk in the context of thrombocytopenia 2, 3

Fever and Pain Management

• Use acetaminophen (paracetamol) as first-line antipyretic and analgesic 1, 2
• However, be aware that acetaminophen carries hepatotoxicity risk, particularly concerning given dengue's frequent hepatic complications 2
• Recent evidence suggests ibuprofen at over-the-counter doses (up to 1,200 mg/day) shows minimal bleeding risk and may provide superior analgesia compared to acetaminophen, though this contradicts traditional guidelines 2

Anti-diarrheal agents, steroids (except for vasopressor-refractory shock), stimulants, and purgatives are contraindicated 1

Clinical Phase Management

Febrile Phase (Days 1-3)

• Maintain oral hydration when possible 4
• Monitor for warning signs: abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, liver enlargement, rising hematocrit with falling platelets 5, 4

Critical Phase (Days 4-7)

• This is when plasma leakage occurs—the period requiring most intensive monitoring and fluid management 5, 6, 3
• Avoid fluid overload which can precipitate pulmonary edema or adult respiratory distress syndrome 1, 6
• If fluid restriction becomes necessary due to pulmonary edema, add norepinephrine as vasopressor 6
• Prophylactic platelet transfusion is not recommended; transfuse only for active bleeding with severe thrombocytopenia 4

Recovery Phase (Days 8-10)

• Reduce and discontinue IV fluids promptly to avoid fluid overload complications 6
• Monitor for reabsorption of extravasated fluid 3

Specific Monitoring Parameters

• Hematocrit levels (rising hematocrit indicates hemoconcentration from plasma leakage) 6, 3
• Platelet counts 4
• Liver function (dengue frequently causes hepatitis) 2
• Urine output 1
• Vital signs including pulse pressure (narrowing indicates worsening shock) 1

Diagnostic Confirmation

• RT-PCR or NS1 antigen detection up to day 5 of illness 1, 5
• IgM antibody testing from day 5-7 onward 1
• Note that cross-reactivity with other flaviviruses (yellow fever, Japanese encephalitis, Zika) can complicate serologic interpretation 1

Special Populations

Children

• Use same 20 mL/kg crystalloid bolus approach 1
• Colloids show benefit in pediatric severe dengue shock syndrome 1
• Avoid routine bolus fluids in febrile illness without confirmed shock (based on FEAST trial showing harm in African children with severe febrile illness) 1

Older Adults

• Face higher mortality risk due to immune dysfunction and comorbidities 7
• Require more cautious fluid management given increased risk of fluid overload 7
• May present with atypical symptoms complicating diagnosis 7